Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on July 20, 2023, specifically the Company's 2023 Annual Meeting of Stockholders. Phio Pharmaceuticals Corp. is a Delaware corporation with its principal executive offices in Marlborough, Massachusetts, and its common stock trades on The Nasdaq Capital Market under the symbol "PHIO."
Key Financial Metrics
This filing is a corporate governance report and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Corporate Actions
The following material actions were approved by stockholders at the Annual Meeting:
- Director Elections: Five directors were elected to serve until the 2024 Annual Meeting: Robert J. Bitterman, Patricia A. Bradford, Robert L. Ferrara, Jonathan E. Freeman, Ph.D., and Curtis A. Lockshin, Ph.D.
- Auditor Ratification: BDO USA, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2023.
- Equity Plan Amendment: The 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan was amended to increase the number of shares available for issuance by 125,500, bringing the total available shares to 225,500.
Voting Results and Shareholder Participation
As of the record date (May 30, 2023), there were 1,504,565 shares issued and outstanding. A total of 630,100 shares were present or represented at the meeting. All proposals were approved:
- Proposal 1 (Directors): All nominees received majority support with "For" votes ranging from 125,280 to 131,864.
- Proposal 2 (Auditors): 605,026 votes For, 21,903 Against, 3,171 Abstain.
- Proposal 3 (Incentive Plan): 98,254 votes For, 44,696 Against, 1,139 Abstain. Notably, there were 486,011 Broker Non-Votes on this proposal.
Guidance, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the standard incorporation of the proxy statement by reference.
Key Facts for Investor Verification
- Verify the impact of the 125,500 share increase in the 2020 Long Term Incentive Plan on potential future dilution.
- Review the full text of the amended 2020 Plan filed as Exhibit 10.1 for specific terms and vesting schedules.
- Note the significant number of Broker Non-Votes (486,011) on the incentive plan amendment, indicating brokers did not have discretionary authority to vote on this matter for beneficial owners.
- Confirm the re-election of the current board composition for the upcoming fiscal year.